Apr 5
|
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
|
Apr 5
|
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
|
Apr 5
|
‘Pioneering’ lung cancer drug offers hope for patients
|
Apr 5
|
Trending tickers: AMD, Shell, AstraZeneca, HubSpot
|
Apr 5
|
UPDATE 2-AstraZeneca's Imfinzi improves survival in late-stage lung cancer trial
|
Apr 3
|
Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers
|
Apr 2
|
Are You Looking for a High-Growth Dividend Stock?
|
Apr 2
|
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
|
Apr 2
|
AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod
|
Apr 2
|
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
|
Apr 2
|
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
|
Apr 1
|
Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
|
Apr 1
|
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
|
Apr 1
|
AstraZeneca PLC's (LON:AZN) Stock Is Going Strong: Have Financials A Role To Play?
|
Apr 1
|
AstraZeneca gets FDA OK for rare disease drug acquired in Alexion buyout
|
Mar 30
|
20 Countries with the Highest Age Dependency Ratio in the World
|
Mar 28
|
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
|
Mar 28
|
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years
|
Mar 27
|
Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data
|
Mar 26
|
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
|